Your New Product: Is the Juice Worth the Squeeze?

That's the real question a physician asks — consciously or not — when your sales rep walks out the door.

Here's what life science executives often forget: Time is Money!

• ~80% of physicians are now employees of a plan, hospital, or private equity firm 

• High-volume PCPs see 20–30 patients a day at ~18 minutes each 

• Their day goes beyond patient care: they are charting, staying current, and fitting in time to learn about new products

Physicians are people first and FDA Approval ≠ Adoption

When evaluating a new product, they're not just reading your clinical data. They're asking:

• "How disruptive is this to my workflow?"

• "Will my patients be able to access and afford it and how much time will that take?" 

• "Do I trust this company enough to be an early adopter?"

How the RAMPx Model Helps You View Your New Product’s Value More Accurately

The RAMPx™ model (Realistic Assessment of Market Potential) evaluates new products across 3 core drivers and 12 interrelated adoption factors:

📌 Relative Advantage — How much better is this vs. current standard of care?

📌 Relative Ease of Adoption — How easily can physicians and patients integrate it?

📌 Perceived Risk — How comfortable are physicians and patients being early adopters?

The result is a quantifiable score that tells you what to champion, what to fix, and what to deprioritize — ideally before you've locked in your clinical trial design.

If you're developing a new product and want to understand how physicians will actually evaluate it — not just whether regulators will approve it — I'd welcome a conversation about RAMPx™ and whether it applies to your situation.